WARF - Wisconsin Alumni Research Foundation Patent applications |
Patent application number | Title | Published |
20130230552 | INFLUENZA VIRUSES WITH MUTANT PB2 GENE SEGMENT AS LIVE ATTENUATED VACCINES - The invention provides a recombinant biologically contained influenza virus that is a PB2 knockout virus, e.g., one that is useful to generate a multivalent vaccine, and methods of making and using that virus. | 09-05-2013 |
20120003263 | RECOMBINANT RACCOON POX VIRUS VACCINE AGAINST HIGHLY PATHOGENIC AVIAN INFLUENZA - Vaccines comprising one or more recombinant raccoon pox viruses and methods of using those vaccines to immunize avians. | 01-05-2012 |
20110263554 | SCREEN FOR INHIBITORS OF FILOVIRUS AND USES THEREFOR - The invention provides methods to identify agents useful to prevent, inhibit or treat viral infections, e.g. filovirus infections, as well as compositions having one or more agents to prevent, inhibit or treat viral infection. | 10-27-2011 |
20110236417 | VACCINES COMPRISING MUTANT ATTENUATED INFLUENZA VIRUSES - The invention provides a vaccine comprising an effective amount of an isolated recombinant influenza virus comprising a mutant M gene segment that is mutated so that upon viral replication the mutant M gene expresses a functional M1 protein and a mutant M2 protein with a deletion of the cytoplasmic tail and either lacking a transmembrane domain or having a mutated transmembrane domain. | 09-29-2011 |
20110110978 | HIGH TITER RECOMBINANT INFLUENZA VIRUSES WITH ENHANCED REPLICATION IN VERO CELLS - The invention provides a composition useful to prepare high titer influenza viruses, e.g., in the absence of helper virus, which includes internal genes from an influenza virus vaccine strain or isolate, e.g., one that is safe in humans, for instance, one that does not result in significant disease, and genes from vaccine seed virus isolates which include a HA gene segment with a HA2 sequence encoding a HA2 that confers enhanced growth in cells in culture, such as Vero cells. | 05-12-2011 |
20110081373 | ATTENUATING MUTATIONS IN THE INFLUENZA A VIRUS NEP(=NS2) PROTEIN - The invention provides an isolated attenuated recombinant influenza virus comprising a gene segment comprising a mutant NS2 protein gene, wherein the NS2 protein has at least two substitutions that do not substantially alter the in vitro replication of the virus but are associated with attenuation of the virus in vivo, wherein at least one of the substitutions is a substitution for glutamate. | 04-07-2011 |
20100203114 | MICELLE ENCAPSULATION OF THERAPEUTIC AGENTS - The invention provides 17 AAG encapsulated in micelle particles. The micelles can be comprised of safe poly(ethylene glycol)-block-poly(lactic acid) (PEG-PLA). A significant advantage of PEG-PLA as a carrier is that it is less toxic than Cremophor® EL or DMSO. Additionally, PEG-PLA micelles are easier to handle than DMSO and they do not possess foul odors, which is a problem associated with 17-AAG formulations currently in clinical trials. The invention also provides methods of preparing active agents encapsulated micelles and therapeutic methods of using the micelles and their corresponding formulations, such as for the inhibition of Hsp 90, and/or for the treatment of cancer. | 08-12-2010 |
20100179111 | SIGMA-1 RECEPTOR LIGANDS AND METHODS OF USE - The invention provides compounds of formula I and compositions thereof. The invention further provides methods of using the compounds and compositions. The compounds of the invention can provide high affinity binding to sigma-1 receptors in a mammal. The compounds can exhibit selectivity for the sigma-1 receptor over the sigma-2 receptor. The compounds and compositions of the invention can also be used to treat conditions that involve the sigma-1 receptor, such as addiction, cardiovascular conditions, and cancer, for example, cancer of the breast, lung, prostate, ovarian, colorectal, or the CNS. | 07-15-2010 |
20090270598 | AMPHIPHILES FOR PROTEIN SOLUBILIZATION AND STABILIZATION - The invention provides amphiphiles for manipulating membrane proteins. The amphiphiles can feature carbohydrate-derived hydrophilic groups and branchpoints in the hydrophilic moiety and/or in a lipophilic moiety. Such amphiphiles are useful as detergents for solubilization and stabilization of membrane proteins, including photosynthetic protein superassemblies obtained from bacterial membranes. | 10-29-2009 |
20090264676 | Amino acids and catalytic preparatory methods - The invention provides novel compounds and methods to carry out organocatalytic Michael additions of aldehydes to nitroethylene catalyzed by a proline derivative to provide α-substituted-γ-nitroaldehydes. The reaction can be rendered enantioselective when a chiral pyrrolidine catalyst is used, allowing for Michael adducts in nearly optically pure form (e.g., 96-99% e.e.). The Michael adducts can bear a single substituent or dual substituents adjacent to the carbonyl. The Michael adducts can be efficiently converted to protected γ | 10-22-2009 |
20090203545 | EFFICIENT oriP/EBNA-1 PLASMID VECTOR - The invention provides a recombinant vector comprising a DNA segment having a synthetic origin of DNA synthesis that binds EBNA-1 and is capable of initiating DNA synthesis of sequences linked to the synthetic origin of DNA synthesis and maintaining the linked sequences when in the presence of EBNA-1. The synthetic origin of DNA synthesis comprises at least two binding sites for EBNA-1, wherein the two EBNA-1 binding sites are flanked by at least two half-binding sites for TRF2 or at least two binding sites for a protein that enhances the affinity of EBNA-1 for the synthetic origin of DNA synthesis. Further provided are host cells with the vector and methods of using the vector, for instance, ex vivo or in vivo. | 08-13-2009 |